Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592121 · ClinicalTrials.gov registry record · Early Phase 1
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
A Early Phase 1 study, sponsored by Applied Biology.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT03592121 is a Early Phase 1 study that has completed, run by Applied Biology. The registered enrollment target is 3 participants.
The verdict
NCT03592121, a Early Phase 1 study, has completed, sponsored by Applied Biology.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
Interventions
- DRUG Placebo
- DRUG AB-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2019-10-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03592121
The ClinicalTrials.gov registry entry for NCT03592121 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Applied Biology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03592121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03592121 about?
NCT03592121 is a clinical study titled "Study to Investigate the Effect of AB-101 in Breast Cancer Survivors". The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
What is the current status of trial NCT03592121?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2018-07-09. Estimated completion is 2019-10-12.
What interventions are being tested in trial NCT03592121?
The interventions under investigation include: Placebo (DRUG), AB-101 (DRUG).
Who is sponsoring clinical trial NCT03592121?
This trial is sponsored by Applied Biology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.